atacicept   Click here for help

GtoPdb Ligand ID: 9517

Synonyms: TACI-Fc | TACI-Ig
Immunopharmacology Ligand
Comment: Atacicept is a recombinant fusion protein designed to inhibit B cells, being investigated as an intervention in autoimmune diseases [1]. Mechanistically atacicept neutralises the function of two important B-cell activating factors, BAFF (BLyS) and APRIL. Structurally atacicept contains the BLyS/APRIL-binding extracellular portion of the TACI receptor fused to a modified Fc from human IgG1 [3]. One of the important functions of these two factors in autoimmune disease is their ability to induce proliferation of plasma cells and thus increase Ig production, in paticular the production of destructive anti-self antibodies.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for atacicept is claimed in patent WO2002094852 [4].
No information available.
Summary of Clinical Use Click here for help
Atacicept is at various stages of clinical development for different autoimmune conditions- e.g. Phase 2/3 for SLE [2] and Phase 2 for rheumatoid arthritis [6] and optic neuritis (a demyelinating inflammation of the optic nerve) [5].